<p>Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy</p> release_mmnfinpccbdxvfjpst7utqsfwm

by Christophe Hézode, Paul Kwo, Jan Sperl, Peggy Hwang, Jianmin Long, Rohit Talwani, Michael N. Robertson, Barbara Haber

Published in International Journal of Women's Health by Informa UK Limited.

Volume Volume 11p617-628 (2019)

Abstract

Some direct-acting antiviral regimens for hepatitis C virus (HCV) infection pose safety or efficacy concerns if coadministered with drugs containing ethinyl estradiol. The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazoprevir (GZR) in women with HCV genotype (GT)1 or GT4 infection. This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50 mg/GZR 100 mg once daily for 12 weeks in phase 2/3 clinical trials. The primary end point was sustained virologic response at 12 weeks after therapy completion (SVR12). For this analysis, participants were stratified according to whether they received OCP or HRT during the original treatment study. A total of 1,022 women with HCV GT1 or GT4 infection were included (receiving OCP/HRT, n=81; not receiving OCP/HRT, n=941). Most participants receiving OCP/HRT were treatment-naive (79%), noncirrhotic (91.4%), and aged >35 years (71.6%). SVR12 rates were similar in women receiving OCP/HRT and those not receiving OCP/HRT (95.1% vs 96.3%). SVR12 rates remained high across all subgroups within the population receiving OCP/HRT: SVR12 rates were 94.6%, 100%, and 100% in participants with GT1a, GT1b, and GT4 infection, and all women aged 18-35 years achieved SVR (21/21). Treatment-related adverse events occurred in 40.7% (33/81) and 30.1% (283/941) of women receiving and those not receiving OCP/HRT, respectively. The efficacy and safety of EBR/GZR administered for 12 weeks was similar in women receiving OCP/HRT and those not on OCP/HRT. These data indicate that EBR/GZR can be safely used for the treatment of HCV GT1 or GT4 infection in women receiving concomitant OCP/HRT.
In text/plain format

Archived Files and Locations

application/pdf  332.9 kB
file_vswj6vzki5efnbgtkhpipzdt6e
web.archive.org (webarchive)
www.dovepress.com (web)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2019-11-20
Language   en ?
Journal Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registery
ISSN-L:  1179-1411
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: afd4b2ec-b69b-4584-965c-57d359b469be
API URL: JSON